

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the present application:

1-19. (Canceled)

20. (New) A pharmaceutical composition that elevates a dendritic cell precursor level in the blood, said pharmaceutical composition comprising:

MIP-1 α or a functional derivative thereof as the active ingredient; and
a pharmaceutically acceptable carrier.

21. (New) The pharmaceutical composition of claim 20, wherein MIP-1 α is chemically modified with an amphipathic polymer.

22. (New) The pharmaceutical composition of claim 21 or 22, wherein the functional derivative of MIP-1 α is BB-10010.

23. (New) The pharmaceutical composition of claim 21, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.

24. (New) A method of elevating a dendritic cell precursor level in the blood in a patient in need thereof, said method comprising:

administering an effective amount of MIP-1 α or a functional derivative thereof to said patient.

25. (New) The method of claim 24, wherein the administered functional derivative of MIP-1 α is BB-10010.

26. (New) The method of claim 24, wherein the administered functional derivative of MIP-1 α is MIP-1 α or BB-10010 which is chemically modified with an amphipathic polymer.

27. (New) The method of 26, wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.

28. (New) A functional derivative of MIP-1 α , wherein the amphipathic polymer is a partially alkyl-esterified styrene-maleic acid copolymer or a polyethylene glycol derivative.